Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-209-FSP-B3
- Development stage
- Unknown
- Lead developer
- Nouscom
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-209-FSP-B3 is a viral vector-based cancer vaccine component developed by Nouscom as part of the NOUS-209 genetic vaccine platform. It utilizes the Modified Vaccinia Ankara (MVA) platform to deliver a specific subset of 209 shared frameshift peptide (FSP) neoantigens. These neoantigens are highly recurrent in tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), which frequently occur in colorectal, gastric, and endometrial cancers. In clinical practice, MVA-209-FSP-B3 is typically administered as a boost following a priming dose with a Great Ape Adenovirus vector (GAd20-209-FSP). The regimen is designed to induce a broad and polyfunctional T-cell response against cancer cells expressing these shared neoantigens. It is currently being evaluated in Phase 2 clinical trials, often in combination with immune checkpoint inhibitors like pembrolizumab.
- Other names
- Modified Vaccinia Ankara-209-Frameshift Peptides
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on MVA-209-FSP-B3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-209-FSP-B3.